AnaptysBio, Inc. (NASDAQ:ANAB) Position Raised by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 41.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 334,450 shares of the biotechnology company's stock after acquiring an additional 97,200 shares during the period. Victory Capital Management Inc. owned approximately 1.10% of AnaptysBio worth $4,428,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ANAB. Charles Schwab Investment Management Inc. increased its position in AnaptysBio by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company's stock worth $2,199,000 after buying an additional 5,733 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in AnaptysBio during the 4th quarter worth about $311,000. Rhumbline Advisers raised its stake in AnaptysBio by 3.8% in the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock valued at $398,000 after purchasing an additional 1,111 shares during the last quarter. Jennison Associates LLC lifted its holdings in AnaptysBio by 1.6% in the 4th quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company's stock valued at $3,563,000 after purchasing an additional 4,242 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 644 shares during the last quarter.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently weighed in on ANAB shares. HC Wainwright reiterated a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th. Wolfe Research began coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price objective for the company. Truist Financial cut their target price on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a research report on Wednesday, December 18th. JPMorgan Chase & Co. boosted their price target on AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, Wells Fargo & Company raised their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.11.

AnaptysBio Stock Up 2.0 %

Shares of ANAB traded up $0.33 during mid-day trading on Wednesday, reaching $16.47. 510,762 shares of the stock traded hands, compared to its average volume of 534,272. The firm has a market cap of $504.93 million, a price-to-earnings ratio of -2.71 and a beta of 0.02. The stock has a fifty day simple moving average of $16.63 and a 200 day simple moving average of $22.89. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $0.89. The firm had revenue of $43.11 million for the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 33.70% of the stock is owned by insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.